Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGD

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Post by 5baggercallson Sep 30, 2021 1:05pm
121 Views
Post# 33946413

Big Market for this Miracle Drug

Big Market for this Miracle Drug
“As many as 55 million people worldwide suffer from Alzheimer’s disease or dementia, and nearly 10 million new cases are reported each year. To date, there is no cure for Alzheimer’s or dementia and the limited range of symptomatic treatments have a high rate of dissatisfaction.
This has created a massive and growing market, estimated to exceed $19 billion by 2026, with few treatment options available to meet the needs of these patients.”
 

 

Why is there a huge market for this drug???

 

"Unfortunately, side effects associated with AChEIs include severe gastrointestinal distress, such as vomiting and diarrhea. Because of these painful side effects, only around half of patients adhere to treatments for longer than 1 year.
Alpha 1062 has been formulated to address this problem. It delays the absorption of the galantamine as the drug reaches the small intestine. ALPHA-1062 passes through the intestinal wall without triggering the gastrointestinal nervous system. In effect, the body can absorb galantamine with minimal to no side effects."
<< Previous
Bullboard Posts
Next >>